Some patients report unusual sensitivity to alcohol during treatment
The ChEMBL drug registry records tirzepatide at maximum phase 4 (approved), first approval 2022, parenteral, with a first-in-class GIP-agonist designation and a boxed-warning flag
These drugs include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is actually a dual GIP/GLP-1 receptor agonist
Zepbound is approved for adults with obesity, or adults who are overweight and have at least one weight-related health condition such as high blood pressure, type 2 diabetes, or high cholesterol
Most patients experience mild, temporary side effects that improve as their bodies adjust